Evidence map›Paper›PMID 20737209›Full record

ArticleInternational urology and nephrology2011

Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion?

Rebecca Vigen, Rick A Weideman, Robert F Reilly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 5 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Breaking the Cycle of Recurrent Calcium Stone Disease.Advances in kidney disease and health · 2023
    Review
  10. Comparison of the Effect of Hydroalcholic Extract ofAdvances in pharmacological and pharmaceutical sciences · 2023
    Article
  11. Molecular mechanisms altering tubular calcium reabsorption.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  12. Review
  13. Article
  14. Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015
    Article
  15. Observational
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rebecca VigenDepartment of Medicine, VA North Texas Heath Care System, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8856, USA.
Rick A Weideman
Robert F Reilly
VA North Texas Health Care System · USThe University of Texas Southwestern Medical Center · US

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
NIDDK NIH HHS P30 DK079328NIDDK NIH HHS P30DK079328
6 · The paper itself

Abstract

In the 1980s a change occurred in hydrochlorothiazide prescribing practices for hypertension from high-dose (50 mg/day) to low-dose (12.5-25 mg/day) therapy. However, randomized controlled trials (RCT) for prevention of calcium-containing kidney stones (CCKS) employed only high doses (≥ 50 mg/day). We hypothesized that these practices have resulted in underdosing of hydrochlorothiazide for prevention of CCKS. Patients with a filled prescription for thiazide diuretics that underwent a 24-h urine stone risk factor analysis were eligible. Those with evidence that thiazide was prescribed for CCKS were further analyzed. Of 107 patients, 102 were treated with hydrochlorothiazide, 4 with indapamide, and one with chlorthalidone. Only 35% of hydrochlorothiazide-treated patients received 50 mg/day; a dose previously shown to reduce stone recurrence. Fifty-two percent were prescribed 25 mg and 13% 12.5 mg daily, doses that were not studied in RCT. Evidence-based hydrochlorothiazide use was suboptimal regardless of where the patient received care (Nephrology or Endocrinology clinic). In a small subset of patients (n = 6) with 24-h urinary calcium excretion measured at baseline and after 2 hydrochlorothiazide doses (25 and ≥ 50 mg), there was a trend toward decreased urinary calcium excretion as the dose was increased from 25 to ≥ 50 mg/day (p = 0.051). Low-dose hydrochlorothiazide was often used for prevention of CCKS despite the fact that there is no evidence that it is effective in this setting. This may have resulted from a practice pattern of using lower doses for hypertension therapy or a lack of knowledge of RCT results in treatment of CCKS.

Indexed as

AdultAgedAged, 80 and overAnalysis of VarianceChi-Square DistributionChlorthalidoneDose-Response Relationship, DrugEvidence-Based MedicineFemaleHumansHydrochlorothiazideIndapamideKidney CalculiMaleMiddle AgedPractice Patterns, Physicians'ChlorthalidoneHydrochlorothiazideIndapamideSodium Chloride Symporter Inhibitors

Identifiers

PMID20737209
PMCPMC3229098
OpenAlexW2086673831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.